Accretion Pharmaceuticals Ltd (ACCPL) — shareholding pattern, promoter holding, financials and share price
About Accretion Pharmaceuticals Ltd (ACCPL)
Accretion Pharmaceuticals Ltd operates in the Pharmaceuticals industry, within the Healthcare sector. It trades on the NSE as ACCPL and on the BSE under scrip code 94000. Its ISIN is INE0T8T01010.
Incorporated in 2012, Accretion Pharmaceuticals Limited is a pharmaceutical company that manufactures and sells tablets, capsules, and other healthcare products. [1]
Accretion Pharmaceuticals Limited specializes in manufacturing and marketing high-quality generic and branded pharmaceutical formulations. They listed on the NSE Emerge platform in May 2025 and achieved a 40% production capacity increase post-IPO.
The company recorded a remarkable revenue growth of 135.59% in H1 FY '26, driven by a diversified product mix and strategic market expansion.
Listed peers in Pharmaceuticals: Accretion Nutraveda Ltd, Oxygenta Pharmaceutical Ltd, Sanjivani Paranteral Ltd, Parnax Lab Ltd, Bio Medica Laboratories Ltd, Panchsheel Organics Ltd.
Valuation & Returns
10 Jul 2026At ₹157 a share on 10 Jul 2026, Accretion Pharmaceuticals Ltd (ACCPL) was valued at a price-to-earnings ratio of 18.05x against an industry P/E of 36.41x and a price-to-book of 3.19x on a book value of ₹49.21 per share. Solomo computes return on equity of 17.67% and return on capital employed of 20.78% from filed results.
- P/E
- 18.05x
- Industry P/E
- 36.41x
- P/B
- 3.19x
- EPS (TTM)
- ₹8.48
- Book value / share
- ₹49.21
- ROE
- 17.67%
- ROCE
- 20.78%
- ROA
- 12.61%
- Debt / equity
- 0.23x
- Dividend yield
- 0%
- EBITDA margin
- 16.89%
- 52-week range
- ₹157 – ₹157
Ratios are computed from filed results and the last recorded price. Not investment advice.
Financial Performance
Mar 2026In the year ended Mar 2026, Accretion Pharmaceuticals Ltd (ACCPL) reported revenue of ₹89.63 crore, net profit of ₹9.67 crore and earnings per share of ₹8.7. That compares with revenue of ₹57.38 crore and net profit of ₹6.79 crore in Mar 2025. Figures are standalone, as filed with the exchanges.
In the quarter ended Mar 2026, revenue was ₹45.89 crore and net profit ₹4.92 crore (standalone).
| Metric | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|
| Revenue (₹ cr) | 13.35 | 57.38 | 89.63 |
| Net profit (₹ cr) | 1.49 | 6.79 | 9.67 |
| EPS (₹) | 3.72 | 8.31 | 8.7 |
| Measure | 1Y |
|---|---|
| Sales growth | 329.81% |
| Profit growth | 355.70% |
Ownership Summary
Jun 2026As of Jun 2026, promoters hold 73.52% of Accretion Pharmaceuticals Ltd (ACCPL) (unchanged from the previous quarter). Market capitalisation was ₹175 crore on 10 Jul 2026. Shareholding is filed quarterly with BSE and NSE; Solomo carries every filing back to Jun 2025.
Largest disclosed public shareholders in Jun 2026: UNICORN FUND 2.76%. Only stakes above the 1% disclosure threshold are named in filings.
| Quarter | Promoter | Pledged | FII | DII | Public |
|---|---|---|---|---|---|
| Jun 2026 | 73.52% | - | - | - | - |
| Mar 2026 | 73.52% | - | - | - | - |
| Dec 2025 | 73.52% | - | - | - | - |
| Sep 2025 | 73.52% | - | - | - | - |
| Jun 2025 | 73.5% | - | - | - | - |